Indeed, the increased O-GlcNAcylation of CaMKII and subsequent phosphorylation of RyR2 is already established to drive arrhythmias in diabetes, suggesting that prevention of CaMKII O-GlcNAcylation may be a therapeutic strategy [13]. This evidence concerns the gene RYR2 and diabetes mellitus.